SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence.
Adult
Aged
Antibodies, Neutralizing
/ blood
Antibodies, Viral
/ blood
Antibody Specificity
COVID-19
/ immunology
Case-Control Studies
Coronavirus Nucleocapsid Proteins
/ immunology
Female
Host Microbial Interactions
/ immunology
Humans
Longitudinal Studies
Male
Middle Aged
Pandemics
Phosphoproteins
/ immunology
SARS-CoV-2
/ immunology
Spike Glycoprotein, Coronavirus
/ immunology
T Follicular Helper Cells
/ immunology
Time Factors
Viral Matrix Proteins
/ immunology
Young Adult
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
18
06
2021
accepted:
27
06
2021
revised:
28
07
2021
pubmed:
17
7
2021
medline:
6
8
2021
entrez:
16
7
2021
Statut:
epublish
Résumé
T-cell immunity is likely to play a role in protection against SARS-CoV-2 by helping generate neutralizing antibodies. We longitudinally studied CD4 T-cell responses to the M, N, and S structural proteins of SARS-CoV-2 in 26 convalescent individuals. Within the first two months following symptom onset, a majority of individuals (81%) mounted at least one CD4 T-cell response, and 48% of individuals mounted detectable SARS-CoV-2-specific circulating T follicular helper cells (cTfh, defined as CXCR5+PD1+ CD4 T cells). SARS-CoV-2-specific cTfh responses across all three protein specificities correlated with antibody neutralization with the strongest correlation observed for S protein-specific responses. When examined over time, cTfh responses, particularly to the M protein, increased in convalescence, and robust cTfh responses with magnitudes greater than 5% were detected at the second convalescent visit, a median of 38 days post-symptom onset. CD4 T-cell responses declined but persisted at low magnitudes three months and six months after symptom onset. These data deepen our understanding of antigen-specific cTfh responses in SARS-CoV-2 infection, suggesting that in addition to S protein, M and N protein-specific cTfh may also assist in the development of neutralizing antibodies and that cTfh response formation may be delayed in SARS-CoV-2 infection.
Identifiants
pubmed: 34270631
doi: 10.1371/journal.ppat.1009761
pii: PPATHOGENS-D-21-01273
pmc: PMC8318272
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Coronavirus Nucleocapsid Proteins
0
Phosphoproteins
0
Spike Glycoprotein, Coronavirus
0
Viral Matrix Proteins
0
membrane protein, SARS-CoV-2
0
nucleocapsid phosphoprotein, SARS-CoV-2
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1009761Subventions
Organisme : NIAID NIH HHS
ID : F30 AI140829
Pays : United States
Organisme : NIAID NIH HHS
ID : F30 AI155295
Pays : United States
Commentaires et corrections
Type : UpdateOf
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Nat Med. 2020 Sep;26(9):1428-1434
pubmed: 32661393
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
J Immunol. 2016 Aug 1;197(3):983-93
pubmed: 27342848
Nature. 2020 Nov;587(7833):270-274
pubmed: 32726801
Nature. 2021 Mar;591(7851):639-644
pubmed: 33461210
JAMA Netw Open. 2020 May 1;3(5):e209759
pubmed: 32442288
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330
Nat Commun. 2021 Feb 19;12(1):1162
pubmed: 33608522
Emerg Infect Dis. 2020 Aug;26(8):1834-1838
pubmed: 32383638
Nature. 2020 Sep;585(7824):174-177
pubmed: 32901123
J Exp Med. 2020 Nov 2;217(11):
pubmed: 32692348
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Nat Med. 2020 Apr;26(4):453-455
pubmed: 32284614
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Clin Invest. 2018 Jul 2;128(7):3171-3185
pubmed: 29911996
Trends Immunol. 2014 Jun;35(6):278-86
pubmed: 24703588
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Cell. 2020 Jun 25;181(7):1489-1501.e15
pubmed: 32473127
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Vaccine. 2020 Feb 11;38(7):1778-1786
pubmed: 31911030
J Immunol. 2011 May 15;186(10):5556-68
pubmed: 21471443
Sci Transl Med. 2013 Mar 13;5(176):176ra32
pubmed: 23486778
J Exp Med. 2017 Jul 3;214(7):2139-2152
pubmed: 28637884
Immunity. 2013 Oct 17;39(4):758-69
pubmed: 24035365
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Nat Commun. 2020 Jul 6;11(1):3434
pubmed: 32632085
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
J Virol. 2015 Dec 09;90(5):2208-20
pubmed: 26656715
J Immunol. 2015 Nov 15;195(10):4861-72
pubmed: 26466954
J Infect Dis. 2018 Oct 5;218(10):1675-1685
pubmed: 29917084
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
Cell. 2021 Jan 7;184(1):169-183.e17
pubmed: 33296701
Cell. 2020 Oct 1;183(1):143-157.e13
pubmed: 32877699
J Immunol Methods. 2003 Apr 1;275(1-2):19-29
pubmed: 12667667
Proc Natl Acad Sci U S A. 2020 Sep 29;117(39):24384-24391
pubmed: 32913053
Nature. 2020 Oct;586(7830):589-593
pubmed: 32785213
J Clin Invest. 2019 Jul 2;129(8):3185-3200
pubmed: 31264971
J Immunol Methods. 2001 Aug 1;254(1-2):59-66
pubmed: 11406153
PLoS Pathog. 2011 Jan 13;7(1):e1001251
pubmed: 21249232
Immunity. 2013 Oct 17;39(4):770-81
pubmed: 24138884
J Mol Biol. 2020 Sep 4;432(19):5212-5226
pubmed: 32710986
PLoS One. 2017 Oct 24;12(10):e0186998
pubmed: 29065175
Science. 2020 Sep 4;369(6508):
pubmed: 32669297
Nat Commun. 2020 Jul 8;11(1):3410
pubmed: 32641700
N Engl J Med. 2020 Dec 10;383(24):2320-2332
pubmed: 32877576
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
Vaccines (Basel). 2020 May 27;8(2):
pubmed: 32471056
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
PLoS One. 2012;7(7):e40733
pubmed: 22792401
J Clin Invest. 2020 Dec 1;130(12):6588-6599
pubmed: 32841212
Cell Rep Med. 2020 Sep 22;1(6):100081
pubmed: 32839763
J Clin Invest. 2021 Jan 4;131(1):
pubmed: 33119547
J Immunol Methods. 2007 May 31;323(1):39-54
pubmed: 17451739
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
J Virol. 2010 Feb;84(3):1289-301
pubmed: 19906920
Immunol Rev. 2010 Jul;236:110-24
pubmed: 20636812
Cell Mol Immunol. 2020 May;17(5):541-543
pubmed: 32203186